Galapagos

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: Public

Established: 1999-01-01

Employees: 1.1K

Market Cap: $1.9B

Website: http://www.glpg.com

Introduction: Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Clinical Trials

A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis

Phase 1

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: GLPG3667
Drug: Placebo

First Posted Date: 2020-10-20

Last Posted Date: 2021-05-27

Lead Sponsor: Galapagos NV

Target Recruit Count: 30

Registration Number: NCT04594928

Locations: 🇵🇱
WIP Warsaw IBD Point, Warsaw, Poland
🇸🇰
Summit Clinical Research, s.r.o., Bratislava, Slovakia
🇧🇬
MC Comac Medical Ltd., Sofia, Bulgaria

and more 4 locations

A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Phase 2

Terminated

Conditions: Autosomal Dominant Polycystic Kidney Disease

Interventions: Drug: GLPG2737
Drug: Placebo

First Posted Date: 2020-10-08

Last Posted Date: 2024-08-22

Lead Sponsor: Galapagos NV

Target Recruit Count: 66

Registration Number: NCT04578548

Locations: 🇵🇱
DaVita Sp. z o.o. Stacja Dializ, Warsaw, Poland
🇪🇸
Hospital Universitario Dr. Peset, Valencia, Spain
🇪🇸
Nefrologia Clinica C.P., Madrid, Spain

and more 17 locations

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: GLPG3970
Drug: Placebo

First Posted Date: 2020-10-08

Last Posted Date: 2022-07-18

Lead Sponsor: Galapagos NV

Target Recruit Count: 28

Registration Number: NCT04577781

Locations: 🇺🇦
Medical Center Clinic of Modern Rheumatology, Zaporizhzhya, Ukraine
🇧🇬
Medical Center Teodora, Ruse, Bulgaria
🇵🇱
Centrum Medyczne Grunwald, Poznan, Poland

and more 6 locations

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis

Phase 2

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Placebo
Drug: GLPG3970

First Posted Date: 2020-10-08

Last Posted Date: 2023-01-27

Lead Sponsor: Galapagos NV

Target Recruit Count: 31

Registration Number: NCT04577794

Locations: 🇬🇪
Arensia Exploratory Medicine LLC, Tbilisi, Georgia
🇵🇱
Centrum Medyczne PROMED, Kraków, Poland
🇵🇱
Endoskopia Sp. z o.o., Sopot, Poland

and more 12 locations

A Study in Healthy Male Volunteers Investigating the Safety, Absorption and Elimination of Single Doses of GLPG4059

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: GLPG4059 oral suspension
Drug: GLPG4059 tablet
Drug: Placebo

First Posted Date: 2020-10-05

Last Posted Date: 2021-05-11

Lead Sponsor: Galapagos NV

Target Recruit Count: 32

Registration Number: NCT04575818

Locations: 🇳🇱
PRA Health Sciences, Groningen, Netherlands

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Healthy Japanese and Caucasian Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: GLPG1205
Drug: Placebo

First Posted Date: 2020-08-31

Last Posted Date: 2020-12-22

Lead Sponsor: Galapagos NV

Target Recruit Count: 32

Registration Number: NCT04532567

Locations: 🇺🇸
WCCT Global, Cypress, California, United States

A Study in Healthy Volunteers to Compare Different Tablet Formulations of the Test Medicine, GLPG1972, Against the Current Tablet Formulation, and to Assess the Effect Food Has on One of the Test Medicines

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: GLPG1972 - C
Drug: GLPG1972 - A
Drug: GLPG1972 - B

First Posted Date: 2019-10-24

Last Posted Date: 2020-01-13

Lead Sponsor: Galapagos NV

Target Recruit Count: 18

Registration Number: NCT04137341

Locations: 🇬🇧
Quotient Sciences Limited, Nottingham, United Kingdom

A Study in Healthy Male Volunteers to Test How the Test Medicine GLPG1972 is Taken up by the Body When Given by Mouth and Into the Vein as an Injection

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: GLPG1972 film-coated tablets
Drug: [14C]-GLPG1972 oral solution
Drug: [14C]-GLPG1972 solution for infusion

First Posted Date: 2019-10-23

Last Posted Date: 2019-11-20

Lead Sponsor: Galapagos NV

Target Recruit Count: 6

Registration Number: NCT04136327

Locations: 🇬🇧
Quotient Sciences Limited, Nottingham, United Kingdom

A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970

Phase 1

Completed

Conditions: Healthy
Psoriasis

Interventions: Drug: GLPG3970 oral solution
Drug: Placebo oral solution
Drug: GLPG3970 capsule

First Posted Date: 2019-09-27

Last Posted Date: 2021-06-03

Lead Sponsor: Galapagos NV

Target Recruit Count: 100

Registration Number: NCT04106297

Locations: 🇲🇩
Clinical Republican Hospital Arensia Experimental Medicine, Chisinau, Moldova, Republic of
🇺🇦
ARENSIA Exploratory Medicine Unit, Kyiv, Ukraine
🇧🇪
SGS Belgium NV - Clinical Pharmacology Unit Antwerp, Antwerp, Belgium

A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: GLPG3667 oral suspension
Drug: GLPG3667 capsules
Drug: Placebos

First Posted Date: 2019-09-20

Last Posted Date: 2020-07-17

Lead Sponsor: Galapagos NV

Target Recruit Count: 52

Registration Number: NCT04097938

Locations: 🇧🇪
SGS Belgium NV - Clinical Pharmacology Unit Antwerp, Antwerp, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy